ATE307584T1 - Mittel zur förderung und verstärkung der neovaskularisierung - Google Patents
Mittel zur förderung und verstärkung der neovaskularisierungInfo
- Publication number
- ATE307584T1 ATE307584T1 AT98940584T AT98940584T ATE307584T1 AT E307584 T1 ATE307584 T1 AT E307584T1 AT 98940584 T AT98940584 T AT 98940584T AT 98940584 T AT98940584 T AT 98940584T AT E307584 T1 ATE307584 T1 AT E307584T1
- Authority
- AT
- Austria
- Prior art keywords
- angiogenesis
- neovascularization
- enhancement
- promoting
- agent
- Prior art date
Links
- 206010029113 Neovascularisation Diseases 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 230000033115 angiogenesis Effects 0.000 abstract 5
- -1 pyridazinone compound Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP23264497 | 1997-08-28 | ||
| PCT/JP1998/003820 WO1999011268A1 (en) | 1997-08-28 | 1998-08-26 | Neovascularization promoters and neovascularization potentiators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE307584T1 true ATE307584T1 (de) | 2005-11-15 |
Family
ID=16942531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98940584T ATE307584T1 (de) | 1997-08-28 | 1998-08-26 | Mittel zur förderung und verstärkung der neovaskularisierung |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6284758B1 (de) |
| EP (1) | EP1025847B1 (de) |
| JP (1) | JP4352613B2 (de) |
| KR (1) | KR100559192B1 (de) |
| CN (1) | CN1142779C (de) |
| AT (1) | ATE307584T1 (de) |
| AU (1) | AU8886298A (de) |
| CA (1) | CA2301852C (de) |
| DE (1) | DE69832089T2 (de) |
| DK (1) | DK1025847T3 (de) |
| ES (1) | ES2247716T3 (de) |
| TW (1) | TW490303B (de) |
| WO (1) | WO1999011268A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ512754A (en) * | 1998-12-07 | 2002-10-25 | Nissan Chemical Ind Ltd | Remedial agent for erectile dysfunction containing a 3(2H)-pyridazinone derivative |
| AU2004308806B9 (en) * | 2003-12-26 | 2010-01-28 | Nissan Chemical Industries, Ltd. | Neutrophilia inhibitor |
| EP1714654A4 (de) * | 2004-02-09 | 2011-02-16 | Nissan Chemical Ind Ltd | Arzneimittel zur hemmung von vaskulärer intimahyperplasie |
| KR101406415B1 (ko) | 2005-07-15 | 2014-06-19 | 미셀 테크놀로지즈, 인코포레이티드 | 제어된 형태의 약물 분말을 함유하는 중합체 코팅 |
| US20090062909A1 (en) | 2005-07-15 | 2009-03-05 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| CA2667228C (en) | 2006-10-23 | 2015-07-14 | Micell Technologies, Inc. | Holder for electrically charging a substrate during coating |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CN101711137B (zh) | 2007-01-08 | 2014-10-22 | 米歇尔技术公司 | 具有可生物降解层的支架 |
| WO2008105260A1 (ja) * | 2007-02-28 | 2008-09-04 | Ltt Bio-Pharma Co., Ltd. | 下肢切断手術の予後を改善する治療剤 |
| US9433516B2 (en) | 2007-04-17 | 2016-09-06 | Micell Technologies, Inc. | Stents having controlled elution |
| WO2008148013A1 (en) | 2007-05-25 | 2008-12-04 | Micell Technologies, Inc. | Polymer films for medical device coating |
| US8685432B2 (en) * | 2008-03-25 | 2014-04-01 | University Of Utah Research Foundation | Controlled release tissue graft combination biomaterials |
| JP5608160B2 (ja) | 2008-04-17 | 2014-10-15 | ミセル テクノロジーズ、インコーポレイテッド | 生体吸収性の層を有するステント |
| EP2313122B1 (de) | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Medizinische wirkstofffreisetzungsvorrichtung |
| US8834913B2 (en) | 2008-12-26 | 2014-09-16 | Battelle Memorial Institute | Medical implants and methods of making medical implants |
| US20100239635A1 (en) | 2009-03-23 | 2010-09-23 | Micell Technologies, Inc. | Drug delivery medical device |
| JP2012522589A (ja) | 2009-04-01 | 2012-09-27 | ミシェル テクノロジーズ，インコーポレイテッド | 被覆ステント |
| EP2453834A4 (de) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Medizinische wirkstofffreisetzungsvorrichtung |
| EP2531140B1 (de) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent und stenteinsatzsystem mit verbesserter einsetzbarkeit |
| US8795762B2 (en) | 2010-03-26 | 2014-08-05 | Battelle Memorial Institute | System and method for enhanced electrostatic deposition and surface coatings |
| US9554888B2 (en) | 2010-04-20 | 2017-01-31 | University Of Utah Research Foundation | Phase separation sprayed scaffold |
| US10232092B2 (en) | 2010-04-22 | 2019-03-19 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| EP2593039B1 (de) | 2010-07-16 | 2022-11-30 | Micell Technologies, Inc. | Medizinische wirkstofffreisetzungsvorrichtung |
| WO2012166819A1 (en) | 2011-05-31 | 2012-12-06 | Micell Technologies, Inc. | System and process for formation of a time-released, drug-eluting transferable coating |
| CA2841360A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| WO2014123978A2 (en) | 2013-02-05 | 2014-08-14 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
| EP2967803B1 (de) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbierbare biomedizinische implantate |
| EP2996629B1 (de) | 2013-05-15 | 2021-09-22 | Micell Technologies, Inc. | Bioabsorbierbare biomedizinische implantate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208124B (en) | 1990-04-25 | 1993-08-30 | Nissan Chemical Ind Ltd | Process for producing pyridazinone derivatives and pharmaceutical compositions comprising such derivatives as active ingredient |
| CA2063055A1 (en) * | 1991-05-22 | 1992-11-23 | Jacob Eyal | Peptides having thrombospondin-like activity and their therapeutic use |
| JP3666042B2 (ja) * | 1994-01-25 | 2005-06-29 | 日産化学工業株式会社 | ピリダジノン誘導体 |
| IL112695A (en) * | 1994-02-22 | 1999-04-11 | Green Cross Corp | Pharmaceutical compositions containing pyridazinone derivatives |
-
1998
- 1998-08-26 US US09/486,327 patent/US6284758B1/en not_active Expired - Lifetime
- 1998-08-26 EP EP98940584A patent/EP1025847B1/de not_active Expired - Lifetime
- 1998-08-26 KR KR1020007001968A patent/KR100559192B1/ko not_active Expired - Fee Related
- 1998-08-26 WO PCT/JP1998/003820 patent/WO1999011268A1/ja not_active Ceased
- 1998-08-26 DE DE69832089T patent/DE69832089T2/de not_active Expired - Lifetime
- 1998-08-26 JP JP2000508370A patent/JP4352613B2/ja not_active Expired - Fee Related
- 1998-08-26 AT AT98940584T patent/ATE307584T1/de active
- 1998-08-26 AU AU88862/98A patent/AU8886298A/en not_active Abandoned
- 1998-08-26 CN CNB988105799A patent/CN1142779C/zh not_active Expired - Fee Related
- 1998-08-26 DK DK98940584T patent/DK1025847T3/da active
- 1998-08-26 ES ES98940584T patent/ES2247716T3/es not_active Expired - Lifetime
- 1998-08-26 CA CA002301852A patent/CA2301852C/en not_active Expired - Fee Related
- 1998-08-27 TW TW087114142A patent/TW490303B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2247716T3 (es) | 2006-03-01 |
| EP1025847A4 (de) | 2003-01-08 |
| DE69832089T2 (de) | 2006-07-20 |
| US6284758B1 (en) | 2001-09-04 |
| AU8886298A (en) | 1999-03-22 |
| EP1025847A1 (de) | 2000-08-09 |
| CA2301852A1 (en) | 1999-03-11 |
| TW490303B (en) | 2002-06-11 |
| DE69832089D1 (de) | 2005-12-01 |
| EP1025847B1 (de) | 2005-10-26 |
| KR100559192B1 (ko) | 2006-03-13 |
| DK1025847T3 (da) | 2006-02-13 |
| CA2301852C (en) | 2007-07-10 |
| KR20010023331A (ko) | 2001-03-26 |
| JP4352613B2 (ja) | 2009-10-28 |
| CN1277553A (zh) | 2000-12-20 |
| WO1999011268A1 (en) | 1999-03-11 |
| CN1142779C (zh) | 2004-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69832089D1 (de) | Mittel zur förderung und verstärkung der neovaskularisierung | |
| ATE334978T1 (de) | Zusammensetzungen und therapeutische anwendungen von isoflavonen und deren analoga | |
| SE9903759D0 (sv) | Pharmaceutically active compounds | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| DK2314582T3 (da) | Heterocykliske forbindelser som antivirusmidler | |
| TR200200579T2 (tr) | Amino-tirazolpiridin türevleri. | |
| BR0214277A (pt) | Solvatos de paclitaxel | |
| ITRM990338A0 (it) | Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria. | |
| ATE288893T1 (de) | Polymorphe form von atorvastatin-calcium | |
| ATE221770T1 (de) | Topische mittel | |
| DE69724777D1 (de) | Pentafluorobenzensulfonamiden und analoge | |
| ATE530197T1 (de) | Medizinische zusammensetzungen zur angiogenese- therapie | |
| DK0889876T3 (da) | Meta-substituerede phenylensulfonamidderivater | |
| BR9804027A (pt) | Novos beta-ceto ésteres | |
| DE60013468D1 (de) | Antimikrobielle mischungen von 1,3-bis(hydroxymethyl)-5,5-dimethylhydantoin und 1,2-benzisothiazolin-3-on | |
| BR0105563A (pt) | Derivados e análogos de galantamina | |
| ATE417617T1 (de) | Mittel zur steurung der expression von il-12 | |
| DE60330391D1 (de) | Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel | |
| TR199801268T2 (xx) | Ta�ikinin antagonistleri olarak 3-Azetidinilalkilpiperidinler veya pirolidinler. | |
| BRPI0417007A (pt) | agentes antivirais de diazaindol-dicarbonil-piperazinila | |
| ATE479657T1 (de) | N-(aryl)-2-arylethensulfonamide und ihre therapeutischen anwendungen | |
| DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
| EP1454903A4 (de) | Thiadiazolinderivat | |
| ATE295183T1 (de) | Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten | |
| ATE253359T1 (de) | Antithrombotische mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1025847 Country of ref document: EP |